224 related articles for article (PubMed ID: 34725436)
1. EZH1/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinoma.
Kusakabe Y; Chiba T; Oshima M; Koide S; Rizq O; Aoyama K; Ao J; Kaneko T; Kanzaki H; Kanayama K; Maeda T; Saito T; Nakagawa R; Kobayashi K; Kiyono S; Nakamura M; Ogasawara S; Suzuki E; Nakamoto S; Yasui S; Mikata R; Muroyama R; Kanda T; Maruyama H; Kato J; Mimura N; Ma A; Jin J; Zen Y; Otsuka M; Kaneda A; Iwama A; Kato N
Sci Rep; 2021 Nov; 11(1):21396. PubMed ID: 34725436
[TBL] [Abstract][Full Text] [Related]
2. Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition.
Rizq O; Mimura N; Oshima M; Saraya A; Koide S; Kato Y; Aoyama K; Nakajima-Takagi Y; Wang C; Chiba T; Ma A; Jin J; Iseki T; Nakaseko C; Iwama A
Clin Cancer Res; 2017 Aug; 23(16):4817-4830. PubMed ID: 28490465
[No Abstract] [Full Text] [Related]
3. An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1.
Konze KD; Ma A; Li F; Barsyte-Lovejoy D; Parton T; Macnevin CJ; Liu F; Gao C; Huang XP; Kuznetsova E; Rougie M; Jiang A; Pattenden SG; Norris JL; James LI; Roth BL; Brown PJ; Frye SV; Arrowsmith CH; Hahn KM; Wang GG; Vedadi M; Jin J
ACS Chem Biol; 2013; 8(6):1324-34. PubMed ID: 23614352
[TBL] [Abstract][Full Text] [Related]
4. Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia.
Xu B; On DM; Ma A; Parton T; Konze KD; Pattenden SG; Allison DF; Cai L; Rockowitz S; Liu S; Liu Y; Li F; Vedadi M; Frye SV; Garcia BA; Zheng D; Jin J; Wang GG
Blood; 2015 Jan; 125(2):346-57. PubMed ID: 25395428
[TBL] [Abstract][Full Text] [Related]
5. Structure-Activity Relationship Studies for Enhancer of Zeste Homologue 2 (EZH2) and Enhancer of Zeste Homologue 1 (EZH1) Inhibitors.
Yang X; Li F; Konze KD; Meslamani J; Ma A; Brown PJ; Zhou MM; Arrowsmith CH; Kaniskan HÜ; Vedadi M; Jin J
J Med Chem; 2016 Aug; 59(16):7617-33. PubMed ID: 27468126
[TBL] [Abstract][Full Text] [Related]
6. Yin Yang 1-mediated epigenetic silencing of tumour-suppressive microRNAs activates nuclear factor-κB in hepatocellular carcinoma.
Tsang DP; Wu WK; Kang W; Lee YY; Wu F; Yu Z; Xiong L; Chan AW; Tong JH; Yang W; Li MS; Lau SS; Li X; Lee SD; Yang Y; Lai PB; Yu DY; Xu G; Lo KW; Chan MT; Wang H; Lee TL; Yu J; Wong N; Yip KY; To KF; Cheng AS
J Pathol; 2016 Apr; 238(5):651-64. PubMed ID: 26800240
[TBL] [Abstract][Full Text] [Related]
7. Polycomb Repressive Complex 2 Proteins EZH1 and EZH2 Regulate Timing of Postnatal Hepatocyte Maturation and Fibrosis by Repressing Genes With Euchromatic Promoters in Mice.
Grindheim JM; Nicetto D; Donahue G; Zaret KS
Gastroenterology; 2019 May; 156(6):1834-1848. PubMed ID: 30689973
[TBL] [Abstract][Full Text] [Related]
8. Sex-biased genetic programs in liver metabolism and liver fibrosis are controlled by EZH1 and EZH2.
Lau-Corona D; Bae WK; Hennighausen L; Waxman DJ
PLoS Genet; 2020 May; 16(5):e1008796. PubMed ID: 32428001
[TBL] [Abstract][Full Text] [Related]
9. Akt inhibition synergizes with polycomb repressive complex 2 inhibition in the treatment of multiple myeloma.
Rizk M; Rizq O; Oshima M; Nakajima-Takagi Y; Koide S; Saraya A; Isshiki Y; Chiba T; Yamazaki S; Ma A; Jin J; Iwama A; Mimura N
Cancer Sci; 2019 Dec; 110(12):3695-3707. PubMed ID: 31571328
[TBL] [Abstract][Full Text] [Related]
10. [Epigenetic aberrations in adult T-cell leukemia/lymphoma and development of a novel EZH1/2 inhibitor].
Yamagishi M
Rinsho Ketsueki; 2018; 59(4):432-438. PubMed ID: 29743404
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib suppresses growth and survival of hepatoma cells by accelerating degradation of enhancer of zeste homolog 2.
Wang S; Zhu Y; He H; Liu J; Xu L; Zhang H; Liu H; Liu W; Liu Y; Pan D; Chen L; Wu Q; Xu J; Gu J
Cancer Sci; 2013 Jun; 104(6):750-9. PubMed ID: 23421437
[TBL] [Abstract][Full Text] [Related]
12. Novel orally bioavailable EZH1/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor.
Honma D; Kanno O; Watanabe J; Kinoshita J; Hirasawa M; Nosaka E; Shiroishi M; Takizawa T; Yasumatsu I; Horiuchi T; Nakao A; Suzuki K; Yamasaki T; Nakajima K; Hayakawa M; Yamazaki T; Yadav AS; Adachi N
Cancer Sci; 2017 Oct; 108(10):2069-2078. PubMed ID: 28741798
[TBL] [Abstract][Full Text] [Related]
13. Mutual regulation between CHD5 and EZH2 in hepatocellular carcinoma.
Xie CR; Li Z; Sun HG; Wang FQ; Sun Y; Zhao WX; Zhang S; Zhao WX; Wang XM; Yin ZY
Oncotarget; 2015 Dec; 6(38):40940-52. PubMed ID: 26517514
[TBL] [Abstract][Full Text] [Related]
14. The functional and mechanistic relatedness of EZH2 and menin in hepatocellular carcinoma.
Gao SB; Xu B; Ding LH; Zheng QL; Zhang L; Zheng QF; Li SH; Feng ZJ; Wei J; Yin ZY; Hua X; Jin GH
J Hepatol; 2014 Oct; 61(4):832-9. PubMed ID: 24845612
[TBL] [Abstract][Full Text] [Related]
15. A CCRK-EZH2 epigenetic circuitry drives hepatocarcinogenesis and associates with tumor recurrence and poor survival of patients.
Feng H; Yu Z; Tian Y; Lee YY; Li MS; Go MY; Cheung YS; Lai PB; Chan AM; To KF; Chan HL; Sung JJ; Cheng AS
J Hepatol; 2015 May; 62(5):1100-11. PubMed ID: 25500144
[TBL] [Abstract][Full Text] [Related]
16. EZH2 represses target genes through H3K27-dependent and H3K27-independent mechanisms in hepatocellular carcinoma.
Gao SB; Zheng QF; Xu B; Pan CB; Li KL; Zhao Y; Zheng QL; Lin X; Xue LX; Jin GH
Mol Cancer Res; 2014 Oct; 12(10):1388-97. PubMed ID: 24916103
[TBL] [Abstract][Full Text] [Related]
17. Dual inhibition of enhancer of zeste homolog 1/2 overactivates WNT signaling to deplete cancer stem cells in multiple myeloma.
Nakagawa M; Fujita S; Katsumoto T; Yamagata K; Ogawara Y; Hattori A; Kagiyama Y; Honma D; Araki K; Inoue T; Kato A; Inaki K; Wada C; Ono Y; Yamamoto M; Miura O; Nakashima Y; Kitabayashi I
Cancer Sci; 2019 Jan; 110(1):194-208. PubMed ID: 30343511
[TBL] [Abstract][Full Text] [Related]
18. Enhancer of zeste 2 polycomb repressive complex 2 subunit promotes sorafenib resistance of hepatocellular carcinoma though insulin-like growth factor 1 receptor.
Hu J; Zhang J; Sun F; Qi M; Su P; Liu H; Gao L; Jiao M; Wu Z; Xiang L; Han B
Anticancer Drugs; 2019 Aug; 30(7):e0746. PubMed ID: 31305292
[TBL] [Abstract][Full Text] [Related]
19. Focal adhesion kinase depletion reduces human hepatocellular carcinoma growth by repressing enhancer of zeste homolog 2.
Gnani D; Romito I; Artuso S; Chierici M; De Stefanis C; Panera N; Crudele A; Ceccarelli S; Carcarino E; D'Oria V; Porru M; Giorda E; Ferrari K; Miele L; Villa E; Balsano C; Pasini D; Furlanello C; Locatelli F; Nobili V; Rota R; Leonetti C; Alisi A
Cell Death Differ; 2017 May; 24(5):889-902. PubMed ID: 28338656
[TBL] [Abstract][Full Text] [Related]
20. EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency.
Shen X; Liu Y; Hsu YJ; Fujiwara Y; Kim J; Mao X; Yuan GC; Orkin SH
Mol Cell; 2008 Nov; 32(4):491-502. PubMed ID: 19026780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
